Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer

R. J. Morgan, J. H. Doroshow, L. Leong, J. Schriber, S. Shibata, S. Forman, V. Hamasaki, K. Margolin, G. Somlo, J. Alvarnas, M. McNamara, J. Longmate, J. Raschko, W. Chow, S. Vasilev, K. McGonigle, Y. Yen

Research output: Contribution to journal › Article › peer-review